Design Therapeutics, Inc.
6.49-0.19 (-2.84%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · DSGN · USD
Key Stats
Market Cap
369.59MP/E (TTM)
-Basic EPS (TTM)
-1.12Dividend Yield
0%Recent Filings
8-K
Board director transition announced
Design Therapeutics' board saw a seamless shift on September 9, 2025, with Arsani William, M.D., resigning without disagreements, paving the way for Justin Gover's appointment as a Class III director through the 2027 annual meeting and Compensation Committee chair. Gover receives a $40,000 board retainer plus $12,000 for his committee role, alongside an initial option for 30,000 shares vesting over three years and a prorated grant for 15,833 shares over one year. This bolsters governance continuity.
10-Q
Q2 FY2025 results
Design Therapeutics posted a Q2 net loss of $19.1M, up 62% y/y from $11.8M, driven by R&D expenses climbing to $15.7M from $10.5M amid ramped-up clinical work on DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy. Operating losses widened to $21.6M from $15.0M, with no revenue yet and interest income dipping to $2.5M from $3.3M. Cash burn quickened, with operating cash use at $31.2M for the half-year versus $23.7M last year, leaving $216.3M in cash and investments at quarter-end—enough for over a year. No debt weighs on the balance sheet. Yet clinical holds from the FDA on DT-216P2's U.S. start pose delays. Cash runway holds firm. Competition in rare diseases sharpens risks.
8-K
Pipeline advances amid FDA hold
Design Therapeutics unveiled early human PK data for DT-216P2, showing favorable translation from non-human primates and an improved profile over prior formulations for its Friedreich Ataxia program, while advancing the RESTORE-FA Phase 1/2 trial outside the U.S. amid an FDA clinical hold. The company kicked off a Phase 2 biomarker study for DT-168 in Fuchs Endothelial Corneal Dystrophy patients. Cash reserves stand at $216.3 million, funding pipeline progress despite a Q2 net loss of $19.1 million. FDA hold resolution remains uncertain.
8-K
Annual meeting elects directors
Design Therapeutics held its 2025 Annual Meeting on June 10, electing Heather Berger, Ph.D., Rodney Lappe, Ph.D., and John Schmid as Class I directors until 2028, with Berger and Schmid securing strong support while Lappe faced notable withheld votes. Stockholders overwhelmingly ratified Ernst & Young LLP as auditors for the year ending December 31, 2025. Board continuity holds firm.
8-K
Q1 loss widens on R&D push
Design Therapeutics reported Q1 2025 net loss of $17.7 million, up from $11.1 million last year, driven by $15.4 million in R&D expenses amid advancing GeneTAC programs. Favorable Phase 1 data for DT-168 in FECD supports a Phase 2 biomarker trial in H2 2025, while the DT-216P2 FA trial progresses to patient dosing mid-year. Cash stands at $229.7 million, funding operations into 2029. Chris Storgard joined as CMO in April. Pipeline advances steadily.
DMAC
DiaMedica Therapeutics Inc.
6.69-0.10
DYN
Dyne Therapeutics, Inc.
23.63-0.66
EWTX
Edgewise Therapeutics, Inc.
16.33-0.09
FDMT
4D Molecular Therapeutics, Inc.
11.41-0.56
GANX
Gain Therapeutics, Inc.
1.82-0.10
NGNE
Neurogene Inc.
32.67+1.65
PEPG
PepGen Inc.
4.51-0.47
RCKT
Rocket Pharmaceuticals, Inc.
3.78-0.19
RGNX
REGENXBIO Inc.
12.84-0.32
RNAC
Cartesian Therapeutics, Inc.
8.20-0.12